I am a
Home I AM A Search Login

Papers of the Week

2021 Feb 15

Braz J Psychiatry

Nitrous oxide as an adjunctive therapy in major depressive disorder: a randomized controlled double-blind pilot trial.


Guimarães MC, Guimarães TM, Hallak JE, Abrão J, Machado-de-Sousa JP
Braz J Psychiatry. 2021 Feb 15.
PMID: 33605397.


Major depressive disorder (MDD) is related to glutamatergic dysfunction. Antagonists of glutamatergic N-methyl-D-aspartate receptor (NMDAR), such as ketamine, have antidepressant properties. Nitrous oxide (N2O) is also a NMDAR antagonist. Thus, this study aimed to evaluate the effects of augmenting antidepressant treatment with N2O.